Caricamento...
Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis
Introduction: Fingolimod is the first oral drug approved by Food and Drug Administration (FDA) of United States for treating patients with relapsing-remitting multiple sclerosis (RRMS). Fingolimod acts by immunomodulation but there are still much remained about its different effects. Objectives: The...
Salvato in:
| Pubblicato in: | Am J Clin Exp Immunol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
e-Century Publishing Corporation
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6726974/ https://ncbi.nlm.nih.gov/pubmed/31497380 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|